261 related articles for article (PubMed ID: 33420855)
1. Treatment patterns for retinal diseases in patients newly-treated with anti-VEGF agents: A retrospective analysis of claims data from the Japan Medical Data Center database.
Kawasaki R; Bauer M; Bezlyak V; Ogura Y
Jpn J Ophthalmol; 2021 Mar; 65(2):215-226. PubMed ID: 33420855
[TBL] [Abstract][Full Text] [Related]
2. Machine Learning Can Predict Anti-VEGF Treatment Demand in a Treat-and-Extend Regimen for Patients with Neovascular AMD, DME, and RVO Associated Macular Edema.
Gallardo M; Munk MR; Kurmann T; De Zanet S; Mosinska A; Karagoz IK; Zinkernagel MS; Wolf S; Sznitman R
Ophthalmol Retina; 2021 Jul; 5(7):604-624. PubMed ID: 33971352
[TBL] [Abstract][Full Text] [Related]
3. Treatment patterns in patients with age-related macular degeneration and diabetic macular edema: A real-world claims analysis in Dubai.
Kozak I; Gurbaxani A; Safar A; Rao P; Masalmeh A; Assaf H; Farghaly M; Pathak P; Natarajan A; Saffar I
PLoS One; 2021; 16(7):e0254569. PubMed ID: 34255798
[TBL] [Abstract][Full Text] [Related]
4. Burden of diabetic macular oedema in patients receiving antivascular endothelial growth factor therapy in South Korea: a healthcare resource use and cost analysis.
Jeon HL; Lee H; Yoon D; Lee Y; Kim JH; Jee D; Shin JY
BMJ Open; 2020 Dec; 10(12):e042484. PubMed ID: 33376178
[TBL] [Abstract][Full Text] [Related]
5. Delayed anti-VEGF injections during the COVID-19 pandemic and changes in visual acuity in patients with three common retinal diseases: A systematic review and meta-analysis.
Im JHB; Jin YP; Chow R; Dharia RS; Yan P
Surv Ophthalmol; 2022; 67(6):1593-1602. PubMed ID: 35970234
[TBL] [Abstract][Full Text] [Related]
6. Maintenance of Vision Needed to Drive after Intravitreal Anti-VEGF Therapy in Patients with Neovascular Age-related Macular Degeneration and Diabetic Macular Edema.
Emami-Naeini P; Garmo V; Boucher N; Fernando R; Menezes A
Ophthalmol Retina; 2024 Apr; 8(4):388-398. PubMed ID: 37866681
[TBL] [Abstract][Full Text] [Related]
7. KSI-301: an investigational anti-VEGF biopolymer conjugate for retinal diseases.
Stern HD; Hussain RM
Expert Opin Investig Drugs; 2022 May; 31(5):443-449. PubMed ID: 35285359
[TBL] [Abstract][Full Text] [Related]
8. Real world evidence of use of anti-VEGF therapy in Denmark.
Vorum H; Olesen TK; Zinck J; Størling Hedegaard M
Curr Med Res Opin; 2016 Dec; 32(12):1943-1950. PubMed ID: 27494692
[TBL] [Abstract][Full Text] [Related]
9. Five-year visual acuity outcomes and injection patterns in patients with pro-re-nata treatments for AMD, DME, RVO and myopic CNV.
Wecker T; Ehlken C; Bühler A; Lange C; Agostini H; Böhringer D; Stahl A
Br J Ophthalmol; 2017 Mar; 101(3):353-359. PubMed ID: 27215744
[TBL] [Abstract][Full Text] [Related]
10. Factors affecting compliance to intravitreal anti-vascular endothelial growth factor therapy in Indian patients with retinal vein occlusion, age-related macular degeneration, and diabetic macular edema.
Kelkar A; Webers C; Shetty R; Kelkar J; Labhsetwar N; Pandit A; Malode M; Tidke S
Indian J Ophthalmol; 2020 Oct; 68(10):2143-2147. PubMed ID: 32971626
[TBL] [Abstract][Full Text] [Related]
11. Anti-vascular endothelial growth factor treatment for retinal conditions: a systematic review and meta-analysis.
Pham B; Thomas SM; Lillie E; Lee T; Hamid J; Richter T; Janoudi G; Agarwal A; Sharpe JP; Scott A; Warren R; Brahmbhatt R; Macdonald E; Straus SE; Tricco AC
BMJ Open; 2019 May; 9(5):e022031. PubMed ID: 31142516
[TBL] [Abstract][Full Text] [Related]
12. Recent trends in anti-vascular endothelial growth factor intravitreal injections: a large claims database study in Japan.
Hashimoto Y; Okada A; Matsui H; Yasunaga H; Aihara M; Obata R
Jpn J Ophthalmol; 2023 Jan; 67(1):109-118. PubMed ID: 36508060
[TBL] [Abstract][Full Text] [Related]
13. Aflibercept versus Faricimab in the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Review.
Liberski S; Wichrowska M; Kocięcki J
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012690
[TBL] [Abstract][Full Text] [Related]
14. Individualized treat-and-extend regime for optimization of real-world vision outcome and improved patients' persistence.
Volkmann I; Knoll K; Wiezorrek M; Greb O; Framme C
BMC Ophthalmol; 2020 Mar; 20(1):122. PubMed ID: 32228517
[TBL] [Abstract][Full Text] [Related]
15. Relationship Between Visual Acuity and Retinal Thickness During Anti-Vascular Endothelial Growth Factor Therapy for Retinal Diseases.
Ou WC; Brown DM; Payne JF; Wykoff CC
Am J Ophthalmol; 2017 Aug; 180():8-17. PubMed ID: 28549848
[TBL] [Abstract][Full Text] [Related]
16. Changes in 12-month outcomes over time for age-related macular degeneration, diabetic macular oedema and retinal vein occlusion.
Bhandari S; Nguyen V; Hunt A; Gabrielle PH; Viola F; Mehta H; Manning L; Squirrell D; Arnold J; McAllister IL; Barthelmes D; Gillies M
Eye (Lond); 2023 Apr; 37(6):1145-1154. PubMed ID: 35508721
[TBL] [Abstract][Full Text] [Related]
17. Risk of Systemic Adverse Events after Intravitreal Bevacizumab, Ranibizumab, and Aflibercept in Routine Clinical Practice.
Maloney MH; Payne SR; Herrin J; Sangaralingham LR; Shah ND; Barkmeier AJ
Ophthalmology; 2021 Mar; 128(3):417-424. PubMed ID: 32781110
[TBL] [Abstract][Full Text] [Related]
18. Short term visual and structural outcomes of anti-vascular endothelial growth factor (anti-VEGF) treatment delay during the first COVID-19 wave: A pilot study.
Naravane AV; Mundae R; Zhou Y; Santilli C; van Kuijk FJGM; Nazari H; Yamanuha J; Emerson GG; Koozekanani DD; Montezuma SR
PLoS One; 2021; 16(2):e0247161. PubMed ID: 33596257
[TBL] [Abstract][Full Text] [Related]
19. Quality-adjusted life years in macular oedema due to age-related macular degeneration, diabetes and central retinal vein occlusion: the impact of anti-VEGF agents in a tertiary centre in Greece.
Voutsas NT; Papageorgiou E; Tantou A; Dimitriou VA; Tsironi EE; Kotoula M
Int Ophthalmol; 2022 Sep; 42(9):2673-2684. PubMed ID: 35416615
[TBL] [Abstract][Full Text] [Related]
20. Automated quantification of macular fluid in retinal diseases and their response to anti-VEGF therapy.
Michl M; Fabianska M; Seeböck P; Sadeghipour A; Haj Najeeb B; Bogunovic H; Schmidt-Erfurth UM; Gerendas BS
Br J Ophthalmol; 2022 Jan; 106(1):113-120. PubMed ID: 33087314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
